Glycine Receptor Antibody Associated Progressive Encephalomyelitis Clinical Outcomes (PREM)

This 2025 article titled "Progressive Encephalomyelitis With Rigidity and Myoclonus With Glycine Receptor Antibodies" by Guasp et al., published in Neurology Neuroimmunology Neuroinflammation aims to detail the clinical features and long-term prognosis of patients suffering from Glycine Receptor (GlyR) antibody–mediated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM). Through a retrospective analysis of cases from a laboratory database and a systematic literature review, the authors identified 41 patients to understand the disease's characteristics, which included rapid onset, a male predominance, and frequent brainstem involvement. The findings conclude that GlyR antibody–mediated PERM is a distinct, rapidly progressive, and severe clinical entity, separate from other related stiff-person spectrum disorders, with older age and Intensive Care Unit (ICU) admission being independent predictors of poor outcome.